Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240768 | 0.83 | SLC6A9 (0.58) | SLC6A9MAPK1KMT2ASLC6A5ALDH1A1 | |
| SCHEMBL3257622 | 0.83 | ALDH1A1 (0.38) | SLC6A9KMT2ASLC6A5ALDH1A1HPGD | |
| SCHEMBL3255158 | 0.81 | SLC6A9 (0.37) | SLC6A9KMT2AALDH1A1HPGD | |
| SCHEMBL3233042 | 0.80 | SLC6A9 (0.52) | SLC6A9SLC6A5ALDH1A1HPGD | |
| SCHEMBL3237933 | 0.79 | TAS1R3 (0.46) | SLC6A9KMT2AALDH1A1 | |
| SCHEMBL3237351 | 0.79 | SLC6A9 (0.51) | SLC6A9SLC6A5ALDH1A1HPGD | |
| SCHEMBL8264425 | 0.78 | SLC6A9 (0.50) | SLC6A9KMT2AALDH1A1HPGD | |
| SCHEMBL4357362 | 0.78 | PLK1 (0.50) | SLC6A9CYP1A2KMT2AALDH1A1HPGD | |
| SCHEMBL3238270 | 0.77 | ALDH1A1 (0.57) | SLC6A9MAPK1KMT2AALDH1A1HPGD | |
| SCHEMBL3243717 | 0.77 | SLC6A9 (0.42) | SLC6A9KMT2ASLC6A5ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137428-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137428-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| EP-1833811-B1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LTD (GB) | 2010-06-02 | — | — | EP | disclosed |
| WO-2006067437-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137428-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | SLC18A2, SLC1A2, SLC6A3 | SLC6A9 37/4885MAPK1 2553/4885CYP1A1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.